Physician profile
Aman Ali
NPI 1093908113
$173,892.14
in general payments reported to CMS, 2019-2025
30 companies · $64K in 2025
The $64K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,383 · 2020: $229 · 2021: $12K · 2022: $11K · 2023: $3,179 · 2024: $80K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $127K · Travel and Lodging: $16K · Food and Beverage: $4,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $126,961.66 |
| Travel and Lodging | $15,832.98 |
| Food and Beverage | $4,743.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $55,062.96 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $46,712.98 | 2022-2025 | Dupixent |
| Abbvie INC. | $42,479.58 | 2019-2025 | Creon, Rinvoq, Mavyret |
| Phathom Pharmaceuticals, INC. | $24,566.09 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,066.86 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $545.83 | 2019-2024 | Rebyota |
| Novartis Pharmaceuticals Corporation | $390.18 | 2021-2024 | |
| Fujifilm Healthcare Americas Corporation | $356.75 | 2021-2024 | Fujifilm |
| Novo Nordisk INC | $282.01 | 2022-2025 | Wegovy |
| Pfizer INC. | $210.79 | 2019-2022 | |
| Boston Scientific Corporation | $135.09 | 2021 | |
| W. L. Gore & Associates, INC. | $133.97 | 2021 | |
| Janssen Biotech, INC. | $122.34 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.53 | 2019-2025 | Gattex, Entyvio |
| Gilead Sciences, INC. | $111.46 | 2020-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $93.66 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $73.78 | 2021-2024 | |
| Celgene Corporation | $59.83 | 2022-2023 | Zeposia |
| Medtronic, INC. | $54.49 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $53.01 | 2019 | |
| Daiichi Sankyo INC. | $50.37 | 2019-2020 | |
| Ucb, INC. | $50.34 | 2019 | |
| Merck Sharp & Dohme LLC | $38.34 | 2022-2024 | Dificid, Zinplava |
| Nestle Healthcare Nutrition INC. | $25.48 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.75 | 2020 | |
| Redhill Biopharma INC. | $17.01 | 2021 | |
| Braintree Laboratories, INC. | $16.88 | 2023 | Sutab |
| Shionogi INC | $14.76 | 2019 | |
| Endogastric Solutions, INC | $14.32 | 2023 | Esophyx |
| Axonics, INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.